The Activity of Gabra3 in Breast Cancer Cells and Functional Perspective of Drug Reposittioning


Creative Commons License

Karaosmanoğlu S., Erdemir Üstündağ A. , Balık D.

3. International Convention of Pharmaceuticals and Pharmacies, İstanbul, Türkiye, 26 - 29 Nisan 2016, cilt.1, no.1, ss.1066

  • Cilt numarası: 1
  • Basıldığı Şehir: İstanbul
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayısı: ss.1066

Özet

The Activity of Gabra3 in Breast Cancer Cells and Functional

Perspective of Drug Repositioning

Sena Karaosmanoğlu, Ayşegül Erdemir, Dilek Turgut Balık

Department of Bioengineering, Yıldız Technical University, Istanbul, Turkey

The discovery of human genome sequence has created a revolution in drug discovery towards the end of 20.

century. This big improvement has offered numerous options on the way to convert research findings into drug

development through understanding the molecular basis of diseases [1]. Drug development process involves

significant number of phase studies and compulsory approvals. In total, the production of new drug takes about

10-15 years to validate for clinical use [2]. So, duration of drug development process from bench to the bedside

is one of the most challenging events affecting drug discovery [1]. At this point, drug repositioning is bringing

a really new vision to long and overcosting traditional de novo drug discovery process. Drug repositioning

technology provides the identification of new indications for approved drug which is already developed in order

to treat a disease in ordinary use [3]. A considerable improvement of the repositioned drugs over traditional

drug development process is that since the repurposed drug has already passed all the necessary toxicity and

other tests, there is no need to evaluate these safety processes to start commercial use of medicines [2,3].

Metastasis is an important point affecting breast cancer patient survival rate. In recent history, one research

group has found that GABAA receptor alpha3 (Gabra3), generally expressed in adult brain, is also expressed in

breast cancer and induces promote the growth and spread of the disease related to high expression of Gabra3

[4]. Here, we would like to investigate the expression levels of Gabra3 in MCF-10A breast epithelial cell line and

MCF-7 cancer cell line and search the effect of different chloride channel blockers which are known for

modulating GABA receptors. In accordance with this aim, we have started to grow these cell lines which make

our hypothesis to take a step further. In this regard, drug repositioning can be very useful technology to

identificate a new clinical use for old drugs in many cases such as cancers, rare diseases and central nervous

system disorders [4,5].

References

[1] İpek F., ‘İlaç Yeniden Konumlandırma’, Hacettepe Üniversitesi, Ankara, 2015.

[2] Pessetto Z. et al, NIH Public Access Mol Cancer Ther., 13(10): 2276–2287,(2014).

[3] Wurth, R., et al, Drug Discov Today 21(1): 190-199,(2016).

[4] Gumireddy, K. et al, Nat. Commun. 7:10715, 2016.

[5] Shim J. et al, Int. J. Biol. Sci., 10(7): 652-661,2014.

This study has supported by the Scientific Research Projects Unit of Yıldız Technical University (BAPK) Grant

No: 2016-07-04-YL04

Keywords: drug repositioning, gabra3, breast cancer, metastasis